AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2026)

AbCellera Biologics' Long-Term Investments history runs 7 years deep, the most recent figure standing at $65.3 million for Q1 2026.

• Quarterly Long-Term Investments fell 19.93% year-over-year to $65.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.3 million (down 19.93% YoY) and the FY2025 annual result came in at $62.6 million, down 23.96% from the prior year.
• Long-Term Investments was $65.3 million for Q1 2026 at AbCellera Biologics, up from $62.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $93.3 million in Q3 2025 and bottomed at $57.6 million in Q1 2023.
• A 5-year average of $71.5 million and a median of $66.7 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments jumped 82.94% — and 2025, when it retreated 23.96%.
• AbCellera Biologics' Long-Term Investments stood at $72.5 million in 2022, then fell by 9.08% to $65.9 million in 2023, then rose by 24.81% to $82.3 million in 2024, then declined by 23.96% to $62.6 million in 2025, then rose by 4.36% to $65.3 million in 2026.
• Business Quant data shows ABCL's Long-Term Investments at $65.3 million in Q1 2026, $62.6 million in Q4 2025, and $93.3 million in Q3 2025.